Related references
Note: Only part of the references are listed.A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis
Tobias Berg et al.
BLOOD (2014)
Inhibition of histone methyltransferase EZH2 depletes leukemia stem cell of mixed lineage leukemia fusion leukemia through upregulation of p16
Koki Ueda et al.
CANCER SCIENCE (2014)
Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
Sarah K. Knutson et al.
MOLECULAR CANCER THERAPEUTICS (2014)
An Orally Bioavailable Chemical Probe of the Lysine Methyltransferases EZH2 and EZH1
Kyle D. Konze et al.
ACS CHEMICAL BIOLOGY (2013)
DZNep, inhibitor of S-adenosylhomocysteine hydrolase, down-regulates expression of SETDB1 H3K9me3 HMTase in human lung cancer cells
Ju-Kyung Lee et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation
Wendy Beguelin et al.
CANCER CELL (2013)
Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth
Shivani Garapaty-Rao et al.
CHEMISTRY & BIOLOGY (2013)
Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis
Marieta Caganova et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
An H3K36 Methylation-Engaging Tudor Motif of Polycomb-like Proteins Mediates PRC2 Complex Targeting
Ling Cai et al.
MOLECULAR CELL (2013)
Chromatin proteins and modifications as drug targets
Kristian Helin et al.
NATURE (2013)
Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer
Woojin Kim et al.
NATURE CHEMICAL BIOLOGY (2013)
The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;NrasG12D acute myeloid leukemia
J. Shi et al.
ONCOGENE (2013)
Structure of the Catalytic Domain of EZH2 Reveals Conformational Plasticity in Cofactor and Substrate Binding Sites and Explains Oncogenic Mutations
Hong Wu et al.
PLOS ONE (2013)
Structural Context of Disease-Associated Mutations and Putative Mechanism of Autoinhibition Revealed by X-Ray Crystallographic Analysis of the EZH2-SET Domain
Stephen Antonysamy et al.
PLOS ONE (2013)
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
Sarah K. Knutson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia
Satomi Tanaka et al.
BLOOD (2012)
Cancer Epigenetics: From Mechanism to Therapy
Mark A. Dawson et al.
CELL (2012)
Ezh1 Is Required for Hematopoietic Stem Cell Maintenance and Prevents Senescence-like Cell Cycle Arrest
Isabel Hidalgo et al.
CELL STEM CELL (2012)
A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia
Camille Simon et al.
GENES & DEVELOPMENT (2012)
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
Michael T. McCabe et al.
NATURE (2012)
Inflammasomes in carcinogenesis and anticancer immune responses
Laurence Zitvogel et al.
NATURE IMMUNOLOGY (2012)
Epigenetic protein families: a new frontier for drug discovery
Cheryl H. Arrowsmith et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Polycomb repressive complex 2 is required for MLL-AF9 leukemia
Tobias Neff et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation
Wei Qi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
被撤回的出版物: Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease (Retracted article. See vol. 8, Art no 14005, 2017)
A. Herrera-Merchan et al.
NATURE COMMUNICATIONS (2012)
The role of mutations in epigenetic regulators in myeloid malignancies
Alan H. Shih et al.
NATURE REVIEWS CANCER (2012)
Dependency on the polycomb gene Ezh2 distinguishes fetal from adult hematopoietic stem cells
Makiko Mochizuki-Kashio et al.
BLOOD (2011)
Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor
Scott R. Daigle et al.
CANCER CELL (2011)
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Johannes Zuber et al.
NATURE (2011)
The Polycomb complex PRC2 and its mark in life
Raphael Margueron et al.
NATURE (2011)
Distinct Factors Control Histone Variant H3.3 Localization at Specific Genomic Regions
Aaron D. Goldberg et al.
CELL (2010)
Quantitative Mass Spectrometry of Histones H3.2 and H3.3 in Suz12-deficient Mouse Embryonic Stem Cells Reveals Distinct, Dynamic Post-translational Modifications at Lys-27 and Lys-36
Hye Ryung Jung et al.
MOLECULAR & CELLULAR PROTEOMICS (2010)
Polycomb repressor complex 2 regulates HOXA9 and HOXA10, activating ID2 in NK/T-cell lines
Stefan Nagel et al.
MOLECULAR CANCER (2010)
Selective inhibition of BET bromodomains
Panagis Filippakopoulos et al.
NATURE (2010)
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
Ryan D. Morin et al.
NATURE GENETICS (2010)
Characterization of an antagonistic switch between histone H3 lysine 27 methylation and acetylation in the transcriptional regulation of Polycomb group target genes
Diego Pasini et al.
NUCLEIC ACIDS RESEARCH (2010)
Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas
Christopher J. Sneeringer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Covalent histone modifications - miswritten, misinterpreted and mis-erased in human cancers
Ping Chi et al.
NATURE REVIEWS CANCER (2010)
Switching on Epigenetic Therapy
Sascha Karberg
CELL (2009)
The molecular biology of mixed lineage leukemia
Robert K. Slany
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation
Tina Branscombe Miranda et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger
Gang G. Wang et al.
NATURE (2009)
Ezh1 and Ezh2 Maintain Repressive Chromatin through Different Mechanisms
Raphael Margueron et al.
MOLECULAR CELL (2008)
EZH1 Mediates Methylation on Histone H3 Lysine 27 and Complements EZH2 in Maintaining Stem Cell Identity and Executing Pluripotency
Xiaohua Shen et al.
MOLECULAR CELL (2008)
Mechanisms of transcriptional regulation by MLL and its disruption in acute leukemia
Yali Dou et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2008)
MLL translocations, histone modifications and leukaemia stem-cell development
Andrei V. Krivtsov et al.
NATURE REVIEWS CANCER (2007)
NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis
Gang G. Wang et al.
NATURE CELL BIOLOGY (2007)
Pharmacologic disruption of polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells
Jing Tan et al.
GENES & DEVELOPMENT (2007)
Cancer epigenomics: DNA methylomes and histone-modification maps
Manel Esteller
NATURE REVIEWS GENETICS (2007)
Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia
Tim C. P. Somervaille et al.
CANCER CELL (2006)
Quantitative production of macrophages or neutrophils ex vivo using conditional Hoxb8
GG Wang et al.
NATURE METHODS (2006)
Chromatin immunoprecipitation and microarray-based analysis of protein location
Tong Ihn Lee et al.
NATURE PROTOCOLS (2006)
The language of covalent histone modifications
BD Strahl et al.
NATURE (2000)
Share Paper
